Lacto N-fucopentaose I (LNFPI), a member of the human milk oligosaccharide (HMO) family, has received widespread attention for its importance to infant health. As a leader in the field of nutrition and food, CD BioGlyco provides you with mature and effective strategies for LNFPI production.

Relationship Between LNFPI and HMOs

HMOs, the third largest solid component in breast milk, is considered the first prebiotics to benefit infant health. More than 200 types of free HMOs have been identified, 50%-80% of which are fucosylated oligosaccharides. Fucosylated HMOs can inhibit the growth of Escherichia coli and Campylobacter, and reduce the probability of infants suffering from enteritis. LNFPI is an important fucosylated HMO, which has many biological functions, such as enhancing the expression of pattern recognition receptors and various innate cytokines to regulate innate immune responses, regulating intestinal flora, and ameliorating enterovirus 71 infections by inhibiting apoptosis. As a functional oligosaccharide, it has the potential to be a confectionary ingredient or a functional additive in formula milk powder.

Fig.1 Structures of LNFPI. (Arboe Jennum, et al., 2014)

Advantages and Disadvantages of LNFPI's Production Methods

There are generally three methods to obtain LNFPI: direct isolation from milk, chemical synthesis, and biocatalytic methods. Because the source of human milk is less, it is not suitable for separation and purification as a raw material. Although some breakthroughs have been made in the chemical synthesis of LNFPI, the reaction process requires multi-step group protection and deprotection, as well as the accompanying reagent toxicity and complex reaction conditions. In contrast, Biocatalytic methods are more suitable for commercial production. Whole-cell biotransformation (fermentation) uses enzymes as catalysts to generate LNFPI by using the synthesis pathway of carbohydrates in organisms. And enzyme catalysis (isolated enzyme biotransformation) has shown great advantages due to its good stereo and regioselectivity.

LNFPI Production Service at CD BioGlyco

CD BioGlyco has accumulated a variety of Production methods. In order to achieve efficient production of LNFPl, our technology has been optimized in many aspects, including but not limited to the following:

• Rational design of metabolic pathways
  Fermentation by engineered strains and the fed-batch cultivation of the strains. Such as synthesizing with the engineered Escherichia coli which expresses a recombinant N-acetylglucosaminyltransferase, fucosyltransferase, and galactosyltransferase.
• One-pot glycosylation production using fucose, N-acetyllactosamine, and lactose as raw materials.
• Chemoenzymatic methods
  Utilizing the advantages of exogenous fucosyltransferase to clone the recombinant protein with a strict receptor specificity and express it in E. coli. On the other hand, using metal ions to improve catalytic efficiency and optimizing reaction temperature and time to complete the efficient production.

Advantages of Us

• One-pot synthesis.
• Low-cost production.
• Optimal enzyme expression levels.
• Optimization of strain culture conditions.
• Rich resources of enzyme and bacterial resources.

CD BioGlyco is a trusted operator and is committed to using our expertise in LNFPI production to drive ongoing innovation. If you are interested in our services, please contact us for more detailed information.

Reference:

1. Arboe Jennum, C.; et al. One-pot glycosylations in the synthesis of human milk oligosaccharides. European Journal of Organic Chemistry. 2014(15): 3232-3241.